Hormone Replacement Therapy for Women with Surgical Menopause

Introduction to Surgical Menopause

• Women with surgical menopause before age 45 face a 32% increased risk of stroke (95% CI, 1.43-2.07) compared to those with natural menopause at typical ages 1
• The accelerated decline in estradiol causes rapid rises in LDL cholesterol, declines in HDL cholesterol, increased blood pressure, accelerated bone loss (2% annually in first 5 years), hot flashes, mood lability, vaginal dryness, and increased cardiovascular disease risk 2, 1

HRT Regimen

• The European Society of Human Reproduction and Embryology (ESHRE) guideline explicitly states: "Migraine should not be seen as a contraindication to HRT use by women with POI" (premature ovarian insufficiency) 3
• Since this patient has had a hysterectomy, she requires estrogen-only therapy without progestin 4, 5, 1
• Progestin is only needed to protect against endometrial cancer in women with an intact uterus 4, 1
• Estrogen-alone therapy has a more favorable risk/benefit profile than combined estrogen-progestin 5

HRT Formulation and Dosage

• Transdermal estradiol is the required formulation for this patient due to her migraine history 4, 3, 1
• Transdermal estradiol avoids first-pass hepatic metabolism and has a more favorable cardiovascular and thrombotic risk profile 1
• Start with 50 μg/day estradiol patch (0.05 mg/day), applied twice weekly 1

Duration of Therapy

• HRT should be continued until at least age 51 (the average age of natural menopause), then reassessed 4, 5, 1
• The British Journal of Cancer guideline recommends HRT up to 51 years of age in the absence of contraindications including personal history of breast cancer or venous thromboembolism 4

Benefits of HRT

• 27% reduction in nonvertebral fractures and prevention of accelerated bone loss 1
• Estrogen supplementation reduces or reverses hot flashes, mood lability, vaginal dryness, pelvic soft tissue atrophy, and osteoporosis risk 2, 6
• Reduction in cardiovascular disease risk when initiated within 10 years of menopause 1

Contraindications to HRT

• Active liver disease 1
• History of myocardial infarction or coronary heart disease 1
• History of deep vein thrombosis or pulmonary embolism 1
• History of stroke 1
• Thrombophilic disorders 1
• Known or suspected estrogen-dependent neoplasia (particularly breast cancer) 1
• Antiphospholipid syndrome 1

Monitoring

• Annual clinical review paying particular attention to compliance 7, 3
• No routine monitoring tests required but may be prompted by specific symptoms or concerns 7, 3
• Monitor for abnormal vaginal bleeding (though unlikely without uterus), breast changes, cardiovascular symptoms, and migraine pattern changes 1